Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Galmed Pharmaceuticals Ltd (GLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GLMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.6% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.09M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.51 | 52 Weeks Range 1.15 - 15.10 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 15.10 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.12% | Return on Equity (TTM) -49.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -8494314 | Price to Sales(TTM) - |
Enterprise Value -8494314 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.32 | Shares Outstanding 2258030 | Shares Floating 2015115 |
Shares Outstanding 2258030 | Shares Floating 2015115 | ||
Percent Insiders 2.9 | Percent Institutions 2.55 |
Analyst Ratings
Rating 1 | Target Price 12 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galmed Pharmaceuticals Ltd
Company Overview
History and Background
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing therapies for liver diseases. Founded in 2007, the company has primarily focused on developing Aramchol, a SCD1 modulator for the treatment of NASH and other liver-related conditions. Its history is largely defined by the clinical trials and regulatory pathways pursued for Aramchol.
Core Business Areas
- Pharmaceutical Development: Focused on researching, developing, and potentially commercializing novel therapeutics for liver diseases, primarily NASH.
Leadership and Structure
Details about the leadership team and organizational structure are available on the company's investor relations website. It's a relatively small company.
Top Products and Market Share
Key Offerings
- Aramchol: A SCD1 modulator being developed for Non-Alcoholic Steatohepatitis (NASH). While it was Galmed's lead drug candidate, clinical trial results were not favorable, impacting its potential market share. Key competitors focused on NASH therapies include companies such as Madrigal Pharmaceuticals (MDGL), Viking Therapeutics (VKTX), and Akero Therapeutics (AKRO).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially the sector focusing on liver diseases like NASH, is highly competitive and rapidly evolving. NASH is a significant unmet medical need with a large patient population, attracting substantial investment and research efforts.
Positioning
Historically, Galmed positioned itself as a player in the NASH treatment space with Aramchol. However, due to clinical trial results, its positioning is currently weak relative to companies with more promising pipelines. The company has other therapies that are in the early phases.
Total Addressable Market (TAM)
The NASH market is projected to be billions of dollars. Given the uncertainty around Aramchol's future, Galmed's current positioning places it at a competitive disadvantage with respect to this TAM.
Upturn SWOT Analysis
Strengths
- Focused therapeutic area (liver disease)
- Established preclinical and clinical research capabilities.
Weaknesses
- Dependence on a single drug candidate (Aramchol)
- Limited financial resources compared to larger pharmaceutical companies
- Uncertain clinical trial results
Opportunities
- Potential partnerships or collaborations
- Expansion into other liver disease indications
- Advancement of other pipeline therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies with greater resources
- Patent expirations
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- AKRO
Competitive Landscape
Galmed faces significant disadvantages compared to competitors with more robust pipelines and financial resources. Their competitive advantage relies on successful development of their remaining assets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been tied to the development of Aramchol.
Future Projections: Future projections are uncertain and depend on the results of any ongoing or future clinical trials and strategic decisions about the direction of the company.
Recent Initiatives: Any recent initiatives would likely focus on exploring next steps regarding Aramchol or other pipeline assets.
Summary
Galmed Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on liver diseases. Its future hinges on the potential success of ongoing and future clinical trials. Recent trial results have significantly weakened the company and it needs to look at new strategies for growth. Competition in the NASH market is intense and Galmed must navigate regulatory hurdles and secure partnerships to thrive. Overall, the company faces challenges in terms of product development, market share and profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share information are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galmed Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-03-13 | Co-Founder, President, CEO & Chairman Mr. Allen Baharaff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://galmedpharma.com |
Full time employees 3 | Website https://galmedpharma.com | ||
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.